|Application ||IHC-F, FC, IP|
|Calculated MW||24656 Da|
|Purification||Purified IgG prepared by affinity chromatography on Protein A from ascites|
|Immunogen||Human CTLA-4/human IgG heavy chain fusion protein.|
|Shelf Life||18 months from date of despatch.|
|Other Names||Cytotoxic T-lymphocyte protein 4, Cytotoxic T-lymphocyte-associated antigen 4, CTLA-4, CD152, CTLA4, CD152|
|Target/Specificity||Mouse anti-Human CD152 antibody, clone BNI3 recognizes human CD152, also known as CTLA-4 (cytotoxic T-lymphocyte-associated antigen 4), an inhibitory receptor and negative regulator of T-cell responses. CD152 is a single pass type 1 transmembrane protein belonging to the immunoglobulin superfamily containing a single Ig-v-like domain in the extracellular region.CD152 along with CD28 binds to the co-stimulatory molecules CD80 and CD86 (Azumaet al.1993).Mouse anti-human CD152 antibody, clone BNI3 is able to block ligand binding on the Raji B-cell line (Steineret al.2001) and blocks binding of an alternative clone, BNI8 to CTLA-4/Ig in ELISA. Further studies indicate that clone BNI3 binds to the same epitope as classified anti-CTLA-4 clones 11D4 and 10A8 (Wang et al. In: Leukocyte typing VI 1997 Garland Publishing Inc. pp97-98, Bull World Health Organ. 1997). The cytoplasmic domain of CD152 contains a critical tyrosine at residue 201 phosphorylated by Janus Kinase 2 which subsequently controls surface expression through regulation of CD152 interaction with AP-2 (Shiratoriet al.1997,Chikumaet al.2000). CD152 is expressed primarily as an intracellular antigen with transport to the cell surface under tight regulation of several molecules including Trim, PLD and TIRC7, CD152 also demonstrates rapid internalization once expressed at the cell surface (Valket al.2008). CD152 plays a significant role in maintaining tolerance to self antigens and defects in CD152 presentation and expression has been implicated in a number of autoimmune diseases (Romo-Tenaet al.2013).|
|Preservative & Stabilisers||0.09% Sodium Azide|
|Storage||Store at +4℃ or at -20 ℃.|
|Precautions||Anti-Human CD152 Antibody, clone BNI3 is for research use only and not for use in diagnostic or therapeutic procedures.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
1. Linsley, P.S. et al. (1992) Co-expression and functional co-operation of CTLA-4 and CD28 on activated T lymphocytes.J. Exp. Med. 176: 1595-1604. 2. Kuiper, H.M. et al. (1995) Activated T cells can induce high levels of CTLA-4 expression on B cells.J. Immunol. 155: 1776-1783. 3. Castan, J. et al. (1997) Accumulation of CTLA-4 expressing T lymphocytes in the germinal centres of human lymphoid tissues.Immunology 90: 265-271. 4. Lee, C.C. et al. (2009) The regulatory function of umbilical cord blood CD4(+) CD25(+) T cells stimulated with anti-CD3/anti-CD28 and exogenous interleukin (IL)-2 or IL-15. Pediatr Allergy Immunol. 20: 624-32. 5. Pistillo, M.P. et al. (2003) CTLA-4 is not restricted to the lymphoid cell lineage and can function as a target molecule for apoptosis induction of leukemic cells.Blood. 101: 202-9. 6. Tan, P.H. et al. (2005) Creation of tolerogenic human dendritic cells via intracellular CTLA4: a novel strategy with potential in clinical immunosuppression.Blood. 106: 2936-43. 7. Steiner, K. et al. (2001) Increased expression of CTLA-4 (CD152) by T and B lymphocytes in Wegener's granulomatosis.Clin Exp Immunol. 126: 143-50.1. Chin, L.T. et al. (2008) Immune intervention with monoclonal antibodies targeting CD152 (CTLA-4) for autoimmune and malignant diseases.Chang Gung Med J. 31: 1-15.
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.